Publications by authors named "Ana Lameiras Azevedo"
Introduction: Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19.
Methods: We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities.
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of illness and hospitalization in young children, particularly those under 1 year old.
- In the Valencian Community of Spain, a new monoclonal antibody called nirsevimab was introduced for high-risk children and those under 6 months as a preventive measure for the 2023-2024 RSV season.
- Preliminary results indicate that the immunization campaign achieved 88.5% coverage, with immunized children showing a threefold reduction in RSV incidence and lower hospitalization rates for respiratory infections compared to those who were not immunized.
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.
Influenza Other Respir Viruses
May 2024
Article Synopsis
- The study analyzed data from Spain's surveillance system for severe acute respiratory infections to assess the effect of nirsevimab on infants born from April 1, 2023, onward.
- Researchers compared actual RSV hospitalizations in children under one year old from late 2023 to early 2024 with expected numbers based on previous seasons.
- The results showed a significant reduction in hospitalizations, estimating between 9,364 to 9,875 fewer cases, which represents a 74% to 75% decrease in RSV-related hospitalizations.
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2).
View Article and Find Full Text PDFBackground: Although recommendations to prevent COVID-19 healthcare-associated infections (HAIs) have been proposed, data on their effectivity are currently limited.
Objective: The aim was to evaluate the effectivity of a program of control and prevention of COVID-19 in an academic general hospital in Spain.
Methods: We captured the number of COVID-19 cases and the type of contact that occurred in hospitalized patients and healthcare personnel (HCP).